- Home
- RPRX vs EXAS Comparison
RPRX vs EXAS Comparison
Compare RPRX & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- EXAS
- Stock Information
- Founded
- RPRX 1996
- EXAS 1995
- Country
- RPRX United States
- EXAS United States
- Employees
- RPRX 89
- EXAS N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- EXAS Medical Specialities
- Sector
- RPRX Health Care
- EXAS Health Care
- Exchange
- RPRX Nasdaq
- EXAS Nasdaq
- Market Cap
- RPRX 13.6B
- EXAS 10.5B
- IPO Year
- RPRX 2020
- EXAS N/A
- Fundamental
- Price
- RPRX $30.93
- EXAS $55.48
- Analyst Decision
- RPRX Strong Buy
- EXAS Strong Buy
- Analyst Count
- RPRX 6
- EXAS 17
- Target Price
- RPRX $41.67
- EXAS $72.63
- AVG Volume (30 Days)
- RPRX 3.4M
- EXAS 2.1M
- Earning Date
- RPRX 02-13-2025
- EXAS 02-19-2025
- Dividend Yield
- RPRX 2.74%
- EXAS N/A
- EPS Growth
- RPRX 518.56
- EXAS N/A
- EPS
- RPRX 2.55
- EXAS N/A
- Revenue
- RPRX $2,266,003,000.00
- EXAS $2,692,328,000.00
- Revenue This Year
- RPRX $14.54
- EXAS $11.81
- Revenue Next Year
- RPRX $10.94
- EXAS $11.52
- P/E Ratio
- RPRX $11.99
- EXAS N/A
- Revenue Growth
- RPRX N/A
- EXAS 11.91
- 52 Week Low
- RPRX $24.05
- EXAS $40.62
- 52 Week High
- RPRX $31.66
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- RPRX 75.82
- EXAS 43.08
- Support Level
- RPRX $29.73
- EXAS $51.80
- Resistance Level
- RPRX $31.09
- EXAS $55.20
- Average True Range (ATR)
- RPRX 0.73
- EXAS 2.87
- MACD
- RPRX 0.28
- EXAS -0.04
- Stochastic Oscillator
- RPRX 93.94
- EXAS 37.34
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.